Intelligent drug launch and commercial

"This is the fifth report in our Intelligent biopharma series, which explores the current and future potential of artificial intelligence (AI) across the biopharma value chain.1 This report focuses on how companies can use AI to improve drug launches and their commercial models.

Why launch and commercial activities need to change
In the biopharma value chain, launch and commercial activities enable patients to gain access to new therapies. However, companies are facing increasing challenges in achieving a successful launch, including the escalating costs of drug development, growing competition, mounting pressure to reduce time-to-market, new models of care and ability to pay for new, innovative medicines..." Lire la suite